Jupiter Research Capital (Asia) Ltd’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-6,451
Closed -$3.46M – 934
2026
Q2
$3.46M Buy
6,451
+4,421
+218% +$2.26M 0.39% 51
2026
Q1
$1.06M Buy
+2,030
New +$970K 0.12% 211

Other funds holding MDGL

Jupiter Research Capital (Asia) Ltd's MDGL Position: Q3 2026 in Review

Jupiter Research Capital (Asia) Ltd sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2026, closing a stake of 6,451 shares — an estimated $3.46M sold.

Jupiter Research Capital (Asia) Ltd first reported a position in MDGL in Q1 2026 and held it in 2 quarters. The position peaked at $3.46M in Q2 2026. 407 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Jupiter Research Capital (Asia) Ltd reported no remaining Madrigal Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Jupiter Research Capital (Asia) Ltd sold 6,451 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $3.46M.
  • Jupiter Research Capital (Asia) Ltd first reported a position in Madrigal Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • Jupiter Research Capital (Asia) Ltd's Madrigal Pharmaceuticals position peaked at $3.46M in Q2 2026.
  • 407 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Jupiter Research Capital (Asia) Ltd's 13F filing for Q3 2026, filed 16 Nov 2026.